LENSAR Third Quarter 2023 Earnings: EPS Beats Expectations, Revenues Lag

LENSAR (NASDAQ:LNSR) Third Quarter 2023 Results

Key Financial Results

• Revenue: US$9.80m (up 26% from 3Q 2022).
• Net income: US$2.57m (up from US$3.99m loss in 3Q 2022).
• Profit margin: 26% (up from net loss in 3Q 2022). The move to profitability was primarily driven by lower expenses.
• EPS: US$0.23 (up from US$0.39 loss in 3Q 2022).

All figures shown in the chart above are for the trailing 12 month (TTM) period

LENSAR EPS Beats Expectations, Revenues Fall Short

Revenue missed analyst estimates by 4.0%. Earnings per share (EPS) exceeded analyst estimates.

Looking ahead, revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 7.8% growth forecast for the Medical Equipment industry in the US.

Performance of the American Medical Equipment industry.

The company's shares are up 3.3% from a week ago.

Risk Analysis

Before we wrap up, we've discovered 3 warning signs for LENSAR that you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.